BioSpace News Archive

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for magrolimab, a first-in-class, investigational anti-CD47 monoclonal antibody for the treatment of newly diagnosed myelodysplastic syndrome (MDS).

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey conducted for Oramed by a third party research firm.

Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage company with expertise in protein dysregulation and a diverse pipeline of investigational therapeutics for neurodegenerative and rare peripheral amyloid diseases will hold an investor webcast today at 1:30 PM ET following Roche’s Top Abstract oral presentation of the clinical results from the Phase 2 PASADENA study

Daxor Corporation (NYSE MKT: DXR), an investment company with innovative medical instrumentation and biotechnology operations focused on blood volume measurement, today announces the Company will be participating in the inaugural Sepsis Alliance Summit.

Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of four additional members to its Scientific Advisory Board (SAB).

Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced the agenda for the 9th Annual Fluidigm Mass Cytometry Summit on September 23.

BIOLASE, Inc. announced that it hosted nearly 400 dental professionals last Thursday evening during a panel discussion on the NEW Journal of Periodontology landmark study from the McGuire Institute comparing periodontal flap surgery to BIOLASE’s REPAIR Perio laser protocol in managing periodontitis.

Titan Pharmaceuticals, Inc. announced that its partner, Molteni Farmaceutici, has entered into an exclusive distribution agreement with Accord Healthcare Europe for the commercialization of Sixmo®-, the brand name for Probuphine® in the European Union.

CuraSen Therapeutics, Inc., a privately held clinical-stage biotechnology company, announced that it has dosed its first subjects in a multi-part, Phase 1 clinical study with CST-2032, the company’s first proprietary compound intended for the treatment of neurodegenerative disease.

Canton & Company, a leading healthcare growth and innovation firm, today announced that William Streck, MD, has joined its leadership team